Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 10/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28717721 | 0.98 | EPHX1 (0.34) | CYP1A2EPHX1EPHX2NAAATDP1 | |
| SCHEMBL8047946 | 0.98 | EPHX1 (0.34) | CYP1A2EPHX1EPHX2NAAATDP1 | |
| SCHEMBL8063149 | 0.97 | TDP1 (0.35) | CYP1A2EPHX1EPHX2NAAATDP1 | |
| SCHEMBL28217865 | 0.93 | CYP1A2 (0.38) | CYP1A2EPHX1EPHX2NAAATDP1 | |
| SCHEMBL1953215 | 0.88 | CYP1A2 (0.39) | CYP1A2TDP1 | |
| SCHEMBL25277094 | 0.85 | CYP1A2 (0.35) | CYP1A2TDP1 | |
| SCHEMBL7630994 | 0.84 | TDP1 (0.36) | EPHX1TDP1 | |
| SCHEMBL5655317 | 0.82 | EPHX1 (0.31) | EPHX1EPHX2 | |
| SCHEMBL31421560 | 0.82 | TDP1 (0.37) | EPHX1TDP1 | |
| SCHEMBL16766423 | 0.81 | TDP1 (0.39) | EPHX1EPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974769-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170348282-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348282-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | CYP1A2 909/4885EPHX1 672/4885EPHX2 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.